GANX (Gain Therapeutics, Inc.) Short-Term Debt to Capital

Gain Therapeutics, Inc. (GANX) is a biotech startup whose stability depends on selling technology rights to corporate behemoths, as current FCF remains negative. The price history on the GURU.Markets chart confirms that this metric stands at 0.02. A lack of sales leaves the company dependent on capital investments. The implementation of AI models for protein synthesis optimizes research expenses, although commercial success has not yet been achieved.

This ratio determines the share of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk and the company's dependence on short-term borrowing. By analyzing the trend of short-term accounts payable relative to equity, an investor can correlate the financial stability of Gain Therapeutics, Inc. (GANX) with the costs associated with the intensive development of the SEE-Tx platform and the preparation of drugs for the therapy of Parkinson's and Gaucher diseases.